journal article·2025-06-05Open access

Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment

Zewei Zhang, Fang He, Wenqu Li, Beibei Liu, Cheng Deng, Xiaojuan Qin

Abstract

Osteosarcoma (OS), a prevalent primary malignant bone tumor in children and adolescents, has maintained consistent treatment protocols since the 1970s combining surgery, chemotherapy, and radiotherapy. While effective for localized tumors, these strategies show limited efficacy against metastatic or recurrent cases. Although emerging immunotherapies (PD-1 inhibitors, CAR-T-cell therapy) demonstrate therapeutic potential, their clinical impact remains constrained by the tumor’s low immunogenicity and immunosuppressive microenvironment, resulting in suboptimal response rates. The disease’s aggressive nature and propensity for pulmonary metastasis contribute to poor prognosis, with survival rates showing negligible improvement over five decades despite therapeutic advances, creating substantial clinical and socioeconomic challenges. Recent developments in nanomedicine offer promising solutions for OS treatment optimization. This review systematically examines nanomaterial applications in OS therapy through a materials science lens, analyzing mechanism-specific interventions and highlighting notable advancements from the past five years. We critically evaluate current strategies for enhancing therapeutic efficacy while reducing toxicity profiles, ultimately outlining translational pathways and key challenges in clinical adaptation. The analysis establishes a framework for developing next-generation nanotherapeutic platforms to address persistent limitations in OS management.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · CAR-T cell therapy research · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Clinical Research Center for Medical Imaging in Hubei Province, Wuhan 430022, China

Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China

Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Hubei Province Key Laboratory of Precision Radiation Oncology, Wuhan 430022, China

Funding

the National Natural Science Foundation of China · the Key Research and Development Program of Hubei · the Open Research Fund of Hubei Province Key Laboratory of Precision Radiation Oncology · the Nature Science Foundation of Hubei Province

References (100+)

Show source-provided references
1. New Horizons in the Treatment of Osteosarcoma10.1056/NEJMra2103423 ↗
3. Rathore, R., and Van Tine, B.A. (2021). Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies. J. Clin. Med., 10.10.3390/jcm10061182 ↗
4. Zhao, X., Wu, Q., Gong, X., Liu, J., and Ma, Y. (2021). Osteosarcoma: A review of current and future therapeutic approaches. Biomed. Eng. Online, 20.10.1186/s12938-021-00860-0 ↗
5. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success10.1200/JCO.2014.59.4895 ↗
6. Advances on immunotherapy for osteosarcoma10.1186/s12943-024-02105-9 ↗
7. Translational biology of osteosarcoma10.1038/nrc3838 ↗
8. Using functional nanomaterials to target and regulate the tumor microenvironment: Diagnostic and therapeutic applications10.1002/adma.201300299 ↗
9. Self-Assembled Peptide-Based Nanodrugs: Molecular Design, Synthesis, Functionalization, and Targeted Tumor Bioimaging and Biotherapy10.1002/smll.202205787 ↗
10. Tumor Diagnosis and Therapy Mediated by Metal Phosphorus-Based Nanomaterials10.1002/adma.202103936 ↗
11. Emerging Strategies of Nanomaterial-Mediated Tumor Radiosensitization10.1002/adma.201802244 ↗
12. Chen, C., Wang, S., Wang, J., Yao, F., Tang, X., and Guo, W. (2023). Nanosized drug delivery strategies in osteosarcoma chemotherapy. APL Bioeng., 7.10.1063/5.0137026 ↗
13. Fatema, K.N., Li, L.L., Ahmad, K., Kim, J., and Lee, D.W. (2025). Development of Multifunctional PAA-Alginate-Carboxymethyl Cellulose Hydrogel-Loaded Fiber-Reinforced Biomimetic Scaffolds for Controlled Release of Curcumin. Int. J. Biol. Macromol., 301.10.1016/j.ijbiomac.2025.140449 ↗
14. GSH-Responsive Pt-Based Nanomotor with Improved Doxorubicin Delivery for Synergistic Osteosarcoma Chemotherapy10.1016/j.actbio.2025.02.004 ↗
15. Stimuli-Responsive Nanocomposite Hydrogels for Biomedical Applications10.1002/adfm.202005941 ↗
16. Design and evaluation of a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma10.1016/j.ijpharm.2025.125191 ↗
17. IL-11-Engineered Macrophage Membrane-Coated Reactive Oxygen Species-Responsive Nanoparticles for Targeted Delivery of Doxorubicin to Osteosarcoma
18. Enzymatically Triggered Drug Release from Microgels Controlled by Glucose Concentration10.1021/acsbiomaterials.4c01721 ↗
19. Therapeutic coordination polymers: Tailoring drug release through metal-ligand interactions10.1039/D4SC00732H ↗
20. Cao, J., Zhu, C., Cao, Z., and Ke, X. (2024). CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma. Int. J. Biol. Macromol., 267.10.1016/j.ijbiomac.2024.130915 ↗
21. Sequential drug release nanocomposites for synergistic therapy in disease treatment10.1039/D5TB00026B ↗
22. Phytic acid-modified manganese dioxide nanoparticles oligomer for magnetic resonance imaging and targeting therapy of osteosarcoma10.1080/10717544.2023.2181743 ↗
23. Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors
24. iRGD-Targeted Biosynthetic Nanobubbles for Ultrasound Molecular Imaging of Osteosarcoma10.2147/IJN.S494151 ↗
25. A multifunctional biomimetic nanoplatform for image-guideded photothermal-ferroptotic synergistic osteosarcoma therapy
26. Wei, X., Feng, J., Chen, L., Zhang, C., Liu, Y., Zhang, Y., Xu, Y., Zhang, J., Wang, J., and Yang, H. (2024). METTL3-Mediated m6A Modification of LINC00520 Confers Glycolysis and Chemoresistance in Osteosarcoma via Suppressing Ubiquitination of ENO1. Cancer Lett., 217194.10.1016/j.canlet.2024.217194 ↗
27. Discovery of 2-Amino-3-Cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis10.1021/acs.jmedchem.2c00004 ↗
28. Recent advances in metal-based nanomaterials for malignant bone tumor therapy10.1016/j.ejmech.2025.117427 ↗
29. Bioinspired Tumor-Targeting and Biomarker-Activatable Cell-Material Interfacing System Enhances Osteosarcoma Treatment via Biomineralization10.1002/advs.202302272 ↗
30. Enhancing osteosarcoma therapy through aluminium hydroxide nanosheets-enabled macrophage modulation10.1016/j.ijpharm.2023.123640 ↗
31. Biomimetic Targeted Co-Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma10.1002/advs.202410427 ↗
32. A Nanodrug Combining CD47 and Sonodynamic Therapy Efficiently Inhibits Osteosarcoma Deterioration10.1016/j.jconrel.2023.01.038 ↗
33. An “Outer Piezoelectric and Inner Epigenetic” Logic-Gated PANoptosis for Osteosarcoma Sono-Immunotherapy and Bone Regeneration10.1002/adma.202415814 ↗
34. Lian, H., Zhang, J., Hou, S., Ma, S., Yu, J., Zhao, W., Zhao, D., and Zhang, Z. (2024). Immunotherapy of osteosarcoma based on immune microenvironment modulation. Front. Immunol., 15.10.3389/fimmu.2024.1498060 ↗
35. CGREF1 Modulates Osteosarcoma Proliferation by Regulating the Cell Cycle Through the Wnt/β-Catenin Signaling Pathway10.1186/s10020-024-01038-9 ↗
36. Enhanced pyroptosis induction with pore-forming gene delivery for osteosarcoma microenvironment reshaping
37. Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches10.1016/j.apsb.2024.03.022 ↗
38. Copper-Loaded Nanoheterojunction Enables Superb Orthotopic Osteosarcoma Therapy via Oxidative Stress and Cell Cuproptosis10.1021/acsnano.3c04903 ↗
39. Li, M., Wang, M., Huang, J., Tang, S., Yang, J., Xu, Z., Xu, G., Chen, X., Liu, J., and Yang, C. (2024). High-performance pyrite nano-catalyst driven photothermal/chemodynamic synergistic therapy for Osteosarcoma. J. Nanobiotechnol., 22.10.1186/s12951-024-02419-2 ↗
40. RhRu Alloy-Anchored MXene Nanozyme for Synergistic Osteosarcoma Therapy10.1002/smll.202205511 ↗
41. Metabolism-Regulating Nanozyme System for Advanced Nanocatalytic Cancer Therapy10.1002/smll.202307794 ↗
42. Bone-Targeting Prodrug Mesoporous Silica-Based Nanoreactor with Reactive Oxygen Species Burst for Enhanced Chemotherapy10.1021/acsami.0c08992 ↗
43. W-Doped TiO2 Nanorods for Multimode Tumor Eradication in Osteosarcoma Models Under Single Ultrasound Irradiation10.1021/acsami.1c14701 ↗
44. High-Efficiency Gold Nanoaggregates for NIR LED-Driven Sustained Mild Photothermal Therapy Achieving Complete Tumor Eradication and Immune Enhancement10.1002/adma.202412191 ↗
45. Liang, Y., Wang, C., Yu, S., Fan, Y., Jiang, Y., Zhou, R., Yan, W., and Sun, Y. (2023). IOX1 Epigenetically Enhanced Photothermal Therapy of 3D-Printing Silicene Scaffolds Against Osteosarcoma with Favorable Bone Regeneration. Mater. Today Bio, 23.10.1016/j.mtbio.2023.100887 ↗
46. Luo, T., Jiang, M., Cheng, Z., Lin, Y., Chen, Y., Zhang, Z., Zhou, J., Zhou, W., Yu, X.F., and Li, S. (2023). Biodegradable FePS3 nanoplatform for efficient treatment of osteosarcoma by combination of gene and NIR-II photothermal therapy. J. Nanobiotechnol., 21.10.1186/s12951-023-01961-9 ↗
47. The combination of eddy thermal effect of biodegradable magnesium with immune checkpoint blockade shows enhanced efficacy against osteosarcoma
48. Yu, K., Zhou, H., Xu, Y., Cao, Y., Zheng, Y., and Liang, B. (2023). Engineering a triple-functional magnetic gel driving mutually-synergistic mild hyperthermia-starvation therapy for osteosarcoma treatment and augmented bone regeneration. J. Nanobiotechnol., 21.10.1186/s12951-023-01955-7 ↗
49. Electrical Stimulation Promotes Endocytosis of Magnetic Nanoparticles by Cancer Cells10.1002/smll.202403381 ↗
50. Lukin, I., Erezuma, I., Desimone, M.F., and Zhang, Y.S.A. (2023). Dolatshahi-Pirouz, and G. Orive, Nanomaterial-based drug delivery of immunomodulatory factors for bone and cartilage tissue engineering. Biomater. Adv., 154.10.1016/j.bioadv.2023.213637 ↗
51. Shi, Q., Lu, Y., Zhang, G., Yang, X., Li, R., Zhang, G., Guo, X., Song, J., and Ding, Q. (2022). Multifunctional Mesoporous Silica Nanoparticles for pH-Response and Photothermy Enhanced Osteosarcoma Therapy. Colloids Surf. B Biointerfaces, 217.10.1016/j.colsurfb.2022.112615 ↗
52. FePSe3-Nanosheets-Integrated Cryogenic-3D-Printed Multifunctional Calcium Phosphate Scaffolds for Synergistic Therapy of Osteosarcoma10.1002/smll.202303636 ↗
53. Wang, L., Dai, Z., Bi, J., Chen, Y., Wang, Z., Sun, Z., Ji, Z., Wang, H., Zhang, Y., and Wang, L. (2024). Polydopamine-functionalized calcium-deficient hydroxyapatite 3D-printed scaffold with sustained doxorubicin release for synergistic chemo-photothermal therapy of osteosarcoma and accelerated bone regeneration. Mater. Today Bio, 29.10.1016/j.mtbio.2024.101253 ↗
54. Neodymium and manganese ions co-doped whitlockite for temperature monitoring, photothermal therapy, and bone tissue repair in osteosarcoma10.1016/j.jcis.2023.09.186 ↗
55. Supercritical CO2-Assisted Fabrication of CM-PDA/SF/nHA Nanofibrous Scaffolds for Bone Regeneration and Chemo-Photothermal Therapy Against Osteosarcoma10.1039/D3BM00532A ↗
56. Genetically Engineered-Cell-Membrane Nanovesicles for Cancer Immunotherapy10.1002/advs.202302131 ↗
57. Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer10.1016/j.addr.2022.114340 ↗
58. Lipid Nanovesicles by Microfluidics: Manipulation, Synthesis, and Drug Delivery10.1002/adma.201804788 ↗
59. Beyond Extracellular Vesicles: Hybrid Membrane Nanovesicles as Emerging Advanced Tools for Biomedical Applications10.1002/advs.202303617 ↗
60. Ultrasound-nanovesicles interplay for theranostics10.1016/j.addr.2023.115176 ↗
61. Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., and Chen, T. (2023). Extracellular vesicles: A rising star for therapeutics and drug delivery. J. Nanobiotechnol., 21.10.1186/s12951-023-01973-5 ↗
62. Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect10.2147/IJN.S379917 ↗
63. Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo10.1080/10717544.2022.2141921 ↗
64. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis10.2147/IJN.S372851 ↗
65. Chen, W., Li, Z., Yu, N., Zhang, L., Li, H., Chen, Y., Gong, F., Lin, W., He, X., and Wang, S. (2023). Bone-Targeting Exosome Nanoparticles Activate Keap1/Nrf2/GPX4 Signaling Pathway to Induce Ferroptosis in Osteosarcoma Cells. J. Nanobiotechnol., 21.10.1186/s12951-023-02129-1 ↗
66. Dipsacus Asperoides-Derived Exosomes-Like Nanoparticles Inhibit the Progression of Osteosarcoma via Activating P38/JNK Signaling Pathway10.2147/IJN.S446594 ↗
67. Wang, Z., He, Z., Wan, J., Chen, A., Cheng, P., and Zhu, W. (2024). EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy. J. Nanobiotechnol., 22.10.1186/s12951-024-02372-0 ↗
68. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors10.1016/j.ijbiomac.2020.08.068 ↗
69. HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma10.2147/IJN.S371934 ↗
70. Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating JAK2/STAT3 Pathway10.2147/IJN.S398046 ↗
71. Transportation of AIE-visualized nanoliposomes is dominated by the protein corona10.1093/nsr/nwab068 ↗
72. Osteosarcoma-targeting PtIV prodrug amphiphile for enhanced chemo-immunotherapy via Ca2+ trapping10.1016/j.actbio.2024.12.048 ↗
73. Long circulating liposomal platform utilizing hydrophilic polymer-based surface modification: Preparation, characterisation, and biological evaluation10.1016/j.ijpharm.2024.124465 ↗
74. Ren, K., Cao, X., Zheng, L., Liu, S., Li, L., Cheng, L., Tian, T., Tong, X., Wang, H., and Jiang, L. (2024). Liposomes decorated with β-conglycinin and glycinin: Construction, structure and in vitro digestive stability. Int. J. Biol. Macromol., 269.10.1016/j.ijbiomac.2024.131900 ↗
75. Combined multispectral analysis and molecular docking to research the interaction of soybean isolate protein with different kinds of phospholipid liposomes and its effect on liposome properties10.1016/j.foodchem.2025.143160 ↗
76. Chen, X.-A., Chuang, C.-C., Chen, C.-C., Lee, C.-Y., Chin, C.-Y., Young, J.-J., Bai, M.-Y., and Chuang, C.-C. (2024). Polyelectrolyte-coated liposomes microfluidically assembled in one-step for enhancing cell endocytosis and in-vivo immune responses. Colloids Surf. B Biointerfaces, 241.10.1016/j.colsurfb.2024.114030 ↗
77. Synergistic photothermal-sonodynamic therapy for antibacterial and immune reprogramming in chronic osteomyelitis10.1016/j.jconrel.2025.113612 ↗
78. Zhang, W., Liu, Y., Luo, Y., Xu, J., Zhang, B., Feng, P., Guo, C., Wang, Y., Huang, Z., and Kong, Q. (2025). Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach. Int. J. Biol. Macromol., 304.10.1016/j.ijbiomac.2025.140765 ↗
79. Liposomes and Niosomes: New trends and applications in the delivery of bioactive agents for cancer therapy10.1016/j.ijpharm.2024.124994 ↗
80. Modeling based dynamics mechanism and pathway of liposome penetration in multicellular tumor spheroid for liposome optimization10.1016/j.ijpharm.2025.125237 ↗
81. Han, Z., Peng, X., Yang, Y., Yi, J., Zhao, D., Bao, Q., Long, S., Yu, S.-X., Xu, X.-X., and Liu, B. (2022). Integrated microfluidic-SERS for exosome biomarker profiling and osteosarcoma diagnosis. Biosens. Bioelectron., 217.10.1016/j.bios.2022.114709 ↗
82. Osteosarcoma-Derived Exosomes as Potential PET Imaging Nanocarriers for Lung Metastasis10.1002/smll.202203999 ↗
83. NGR-Modified CAF-Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma10.1002/advs.202410918 ↗
84. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB110.1186/s12943-023-01804-z ↗
85. Osteosarcoma Cell-Derived Migrasomes Promote Macrophage M2 Polarization to Aggravate Osteosarcoma Proliferation and Metastasis10.1002/advs.202409870 ↗
86. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy10.1016/j.jconrel.2022.01.026 ↗
87. PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity10.1038/s41423-020-0487-7 ↗
88. Wang, J., Zhang, H., Sun, X., Wang, X., Ren, T., Huang, Y., Zhang, R., Zheng, B., and Guo, W. (2020). Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. J. Nanobiotechnology, 18.10.1186/s12951-020-00710-6 ↗
89. Bioengineering of virus-like particles as dynamic nanocarriers for in vivo delivery and targeting to solid tumours10.1016/j.addr.2021.114030 ↗
90. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers10.1038/s41551-024-01208-4 ↗
91. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma10.1136/jitc-2020-001703 ↗
92. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma10.2147/IJN.S346685 ↗
93. Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells10.2147/IJN.S452989 ↗
94. Wang, J., Liang, S., Chen, S., Ma, T., Chen, M., Niu, C., Leng, Y., and Wang, L. (2024). Bacterial outer membrane vesicle-cancer cell hybrid membrane-coated nanoparticles for sonodynamic therapy in the treatment of breast cancer bone metastasis. J. Nanobiotechnology, 22.10.1186/s12951-024-02619-w ↗
95. Multimodal layer-by-layer nanoparticles: A breakthrough in gene and drug delivery for osteosarcoma10.1039/D4TB01541J ↗
96. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy10.1080/10717544.2020.1785049 ↗
97. Wang, Y., Zhang, L., Zhao, G., Zhang, Y., Zhan, F., Chen, Z., He, T., Cao, Y., Hao, L., and Wang, Z. (2022). Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms. J. Nanobiotechnology, 20.10.1186/s12951-021-01201-y ↗
98. Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles10.1039/D0BM01296C ↗
99. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma10.1080/10717544.2020.1856221 ↗
100. IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma10.1016/j.jconrel.2022.08.048 ↗